Health Biotchnology is trading at 12.81 as of the 15th of July 2025; that is 0.39 percent increase since the beginning of the trading day. The fund's open price was 12.76. Health Biotchnology has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 16th of April 2025 and ending today, the 15th of July 2025. Click here to learn more.
The fund will normally invest at least 80 percent of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value . Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. More on Health Biotchnology Portfolio
Health Biotchnology Portfolio [SHPCX] is traded in USA and was established 15th of July 2025. Health Biotchnology is listed under Saratoga category by Fama And French industry classification. The fund is listed under Health category and is part of Saratoga family. This fund at this time has accumulated 11.88 M in assets with minimum initial investment of 250. Health Biotchnology is currently producing year-to-date (YTD) return of 2.14%, while the total return for the last 3 years was 2.38%.
Check Health Biotchnology Probability Of Bankruptcy
Instrument Allocation
Top Health Biotchnology Portfolio Mutual Fund Constituents
Other Information on Investing in Health Mutual Fund
Health Biotchnology financial ratios help investors to determine whether Health Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Health with respect to the benefits of owning Health Biotchnology security.
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance